Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) alongside an immunology-focused therapeutic development platform, reported revenue of $2.8 million for the nine months ended Sept. 30, 2026, a 167% increase from $1.05 million in the prior-year period. The growth reflects the expansion of its CDMO operations, including the February acquisition of Recipharm Israel.
The company reported an operating loss of $6.56 million and a net loss of $390,000. The net loss was significantly reduced by a $6.4 million noncash bargain purchase gain related to the acquisition. Scinai also reported approximately $8.32 million in committed customer orders as of Nov. 4, 2026, up more than 330% from year-end 2025. This includes an expanded U.S. customer agreement with approximately $5.1 million in committed base service fees.
In October, Scinai generated approximately $5.3 million in net proceeds from financing transactions, bringing reported bank balances to approximately $8.1 million as of Oct. 27. Based on current projections and anticipated customer payments, the company expects sufficient operating liquidity through late 2027, with potential additional clinical manufacturing work that could extend its runway into 2028. For a deeper look at the full announcement, visit https://ibn.fm/1OlnB.
The results underscore the growing role of Scinai’s CDMO business, which provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. The Recipharm Israel acquisition has clearly accelerated revenue and order flow, and the sizable committed order book offers visibility into future performance. For investors, the combination of strong top-line growth, a strengthened balance sheet, and an extended cash runway may reduce near-term financing risk and support the company’s dual strategy of service revenue and therapeutic development.
Scinai’s therapeutic pipeline includes candidates licensed from the Max Planck Society and from PinCell S.r.l., and the company continues to advance its immunology-focused development platform. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.
The announcement was distributed through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, offering services that include editorial syndication to 5,000+ outlets and social media distribution to millions of followers. For full terms of use and disclaimers applicable to this content, see https://www.InvestorWire.com/Disclaimer.
